167 related articles for article (PubMed ID: 7910154)
1. Doxorubicin retention and chemoresistance in human mesothelioma cell lines.
Isobe H; Wellham L; Sauerteig A; Sridhar KS; Ramachandran C; Krishan A
Int J Cancer; 1994 May; 57(4):581-5. PubMed ID: 7910154
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.
Schott B; Londos-Gagliardi D; Ries C; Huet S; Robert J
J Cancer Res Clin Oncol; 1993; 119(9):527-32. PubMed ID: 8100823
[TBL] [Abstract][Full Text] [Related]
3. MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.
Ramachandran C; Sauerteig A; Sridhar KS; Thurer RJ; Krishan A
Cancer Chemother Pharmacol; 1993; 31(6):431-41. PubMed ID: 8095859
[TBL] [Abstract][Full Text] [Related]
4. Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines.
Ogretmen B; Bahadori HR; McCauley MD; Boylan A; Green MR; Safa AR
Int J Cancer; 1998 Mar; 75(5):757-61. PubMed ID: 9495245
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of multiple drug resistance in human bladder cancer cell lines.
Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
[TBL] [Abstract][Full Text] [Related]
7. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G
J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
Huet S; Schott B; Robert J
Br J Cancer; 1992 Apr; 65(4):538-44. PubMed ID: 1348623
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
Scotlandi K; Serra M; Manara MC; Lollini PL; Maurici D; Del Bufalo D; Baldini N
Int J Cancer; 1994 Jul; 58(1):95-101. PubMed ID: 7912235
[TBL] [Abstract][Full Text] [Related]
10. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase pi gene expression.
Ramachandran C; Yuan ZK; Huang XL; Krishan A
Biochem Pharmacol; 1993 Feb; 45(3):743-51. PubMed ID: 8095141
[TBL] [Abstract][Full Text] [Related]
12. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of doxorubicin-resistant Lewis lung carcinoma variants.
Bruno NA; Carver LA; Slate DL
Cancer Commun; 1990; 2(4):151-8. PubMed ID: 1973357
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of a mouse tumour cell line with in vitro derived resistance to verapamil.
Twentyman PR; Wright KA; Fox NE
Br J Cancer; 1990 Feb; 61(2):279-84. PubMed ID: 1968761
[TBL] [Abstract][Full Text] [Related]
15. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines.
Park JG; Lee SK; Hong IG; Kim HS; Lim KH; Choe KJ; Kim WH; Kim YI; Tsuruo T; Gottesman MM
J Natl Cancer Inst; 1994 May; 86(9):700-5. PubMed ID: 7908989
[TBL] [Abstract][Full Text] [Related]
16. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.
Oudard S; Thierry A; Jorgensen TJ; Rahman A
Cancer Chemother Pharmacol; 1991; 28(4):259-65. PubMed ID: 1678995
[TBL] [Abstract][Full Text] [Related]
18. Differential over-expression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine.
Schott B; Bennis S; Pourquier P; Ries C; Londos-Gagliardi D; Robert J
Int J Cancer; 1993 Aug; 55(1):115-21. PubMed ID: 8102127
[TBL] [Abstract][Full Text] [Related]
19. Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines.
Efferth T; Löhrke H; Volm M
Urol Res; 1990; 18(5):309-12. PubMed ID: 1979457
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro.
Hill BT; van der Graaf WT; Hosking LK; de Vries EG; Mulder NH; Whelan RD
Int J Cancer; 1993 Sep; 55(2):330-7. PubMed ID: 8103761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
